Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B.
Related Research units
Abstract
Tenofovir disoproxil fumarate (TDF), a nucleotide analogue and potent inhibitor of hepatitis B virus (HBV) polymerase, showed superior efficacy to adefovir dipivoxil in treatment of chronic hepatitis B through 48 weeks. We evaluated long-term efficacy and safety of TDF monotherapy in patients with chronic hepatitis B who were positive or negative for hepatitis B e antigen (HBeAg(+) or HBeAg(-)).
Bibliographical data
| Original language | English |
|---|---|
| Article number | 1 |
| ISSN | 0016-5085 |
| Publication status | Published - 2011 |
| pubmed | 20955704 |
|---|
